A 60% reduction in the risk of death—HR 0.40—in previously treated metastatic pancreatic cancer is not a number the oncology community has seen before, in any phase 3 trial, in any line of therapy. That is the threshold RASolute 302 crossed. Revolution Medicines enrolled 500 patients, randomized them between once-daily oral daraxonrasib and investigator’s choice of standard cytotoxic chemotherapy, and watched median overall survival reach 13.2 months on the experimental arm versus 6.6 months on chemotherapy in the RAS G12 mutant population. Doubling median OS in second-line pancreatic ductal adenocarcinoma, a disease where incremental gains have defined ambition for decades, reframes what the endpoint space for this indication even looks like.
The design deserves scrutiny because it strengthens the claim. The trial enrolled patients with or without an identified RAS mutation—the intent-to-treat population produced an identical HR of 0.40—which means the survival signal is not an artifact of exquisite patient selection. That the benefit held across the full ITT population reflects daraxonrasib’s mechanism as a RAS(ON) multi-selective inhibitor targeting constitutive RAS activity regardless of specific variant. Objective response rate hit 33.2% in the RAS G12 population against 11.8% for chemotherapy; PFS HR was 0.45. Every primary and key secondary endpoint cleared. The concurrent New England Journal of Medicine publication eliminates the lag between announcement and peer scrutiny, which matters for how fast this data moves into guideline discussions.
Safety is the variable that will define real-world uptake. Grade 3 or higher treatment-related adverse events occurred in 43.6% of daraxonrasib patients—not trivial, but contextually relevant given that patients on the arm also reported significantly delayed deterioration in cancer-related pain and global health status compared to chemotherapy. Treatment discontinuation due to toxicity was low. For a population where quality of life degrades rapidly under fluorouracil- or irinotecan-based regimens, that functional preservation is a clinical argument in itself, not just a secondary endpoint box.
The immediate regulatory question is NDA timing. Revolution Medicines has phase 3 data with NEJM publication, a plenary ASCO slot, and a clean benefit-risk profile. The speed of a filing and whether FDA grants priority review designation will determine whether this becomes the first RAS-targeted approval in pancreatic cancer before the end of 2026—that filing date is the single marker that now matters most.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
